Drugs / MRKAd5 HIV-1 gag/pol/nef
MRKAd5 HIV-1 gag/pol/nef
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00413725 | Jan 2007 → Aug 2012 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRKAd5 HIV-1 gag/pol/nef | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00413725 ↗ |
| Known as | Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine | “The HVTN 503/Phambili study, which assessed the efficacy of the Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine in South Africa” PMID 24560541 ↗ Feb 2014 |
| Known as | MRK Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine | “The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and efficacy of the MRK Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine vs placebo” PMID 26368824 ↗ Sep 2015 |
| Known as | MRKAd5 HIV-1 gag/pol/nef subtype B vaccine | “The MRKAd5 HIV-1 gag/pol/nef subtype B vaccine was designed to elicit T-cell-mediated immune responses capable of providing complete or partial protection from HIV-1 infection” PMID 21570355 ↗ May 2011 |
| Known as | MRKAd5 HIV-1 Gag/Pol/Nef vaccine | “We investigated the HLA-specific impact of the MRKAd5 HIV-1 Gag/Pol/Nef vaccine in a subset of the infected Phambili cohort” PMID 26951820 ↗ Mar 2016 |
| Known as | MRKAd5 HIV-1 vaccine | “After the lack of efficacy of the MRKAd5 HIV-1 vaccine in the Step study, enrolment and vaccination in our study was halted” PMID 21570355 ↗ May 2011 |
| Modality | Vaccine | “a clade B-based adenovirus serotype 5 HIV-1 vaccine” NCT00413725 ↗ |
| Route | Intramuscular | “The vaccine and placebo were given by intramuscular injection on a 0, 1, 6 month schedule.” PMID 21570355 ↗ May 2011 |